ovarian cancer

Research Reports

Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer

06/05/2023

Emma L. Barber, MD

Allison M. Saiz, MD

Nicole M. Engel-Nitz, PhD

Scott H. Bunner, MPH

Katrine L. Wallace, PhD

Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.

Emma L. Barber, MD, and...

06/05/2023

Journal of Clinical Pathways

News

Ostomy Does Not Worsen Outcomes After Bowel Restrictions for Patients With Ovarian Cancer

07/06/2022

Carol Brzozowski

Whether ostomy worsens survival outcomes is a topic of controversy. Therefore, a research team from China investigated patient outcomes after undergoing ostomy after bowel resections.

Whether ostomy worsens survival...

07/06/2022

Wound Care

David O'Malley, MD, Ohio State University Comprehensive Cancer Center

Videos

Rucaparib Promising for BRCA–Positive Relapsed Ovarian Cancer: Results From the ARIEL4 Trial

07/04/2021

David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA–positive, advanced, relapsed ovarian carcinoma.

David O'Malley, MD, highlights...

07/04/2021

Oncology

News

Optimizing Germline Genetic Testing for Women With Breast or Ovarian Cancer

03/10/2021

Journal of Clinical Pathways

News

Cost-Effectiveness of Genomic Screening for Hereditary Breast and Ovarian Cancer

11/30/2020

Journal of Clinical Pathways

Videos

PROs Comparable Between Niraparib, Placebo in Advanced Ovarian Cancer

11/29/2020

Journal of Clinical Pathways

Videos

HRQoL in Newly Diagnosed Ovarian Cancer Treated With Veliparib

11/28/2020

Journal of Clinical Pathways

Special Report

Overview of the Updated NCCN Guidelines on Ovarian Cancer

06/17/2020

While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...

While...

06/17/2020

Journal of Clinical Pathways

News

PARP Inhibitor vs Nonplatinum Chemo for Platinum-Sensitive, Relapsed Ovarian Cancer

06/09/2020

Olaparib improves survival outcomes for patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who received at least two prior lines of platinum-based chemotherapy, according to a...

...

06/09/2020

Journal of Clinical Pathways

News

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

06/03/2020

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of...

...

06/03/2020

Journal of Clinical Pathways